UBS Group Initiates Coverage on Tempus AI (NASDAQ:TEM)

Equities researchers at UBS Group started coverage on shares of Tempus AI (NASDAQ:TEM) in a report released on Wednesday, Marketbeat.com reports. The firm set a “neutral” rating and a $70.00 price target on the stock. UBS Group’s target price would suggest a potential upside of 8.88% from the stock’s current price.

A number of other equities research analysts also recently commented on TEM. HC Wainwright dropped their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. Guggenheim increased their price objective on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus lowered their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus price target of $68.78.

Tempus AI Price Performance

TEM stock opened at $64.29 on Wednesday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The firm has a market capitalization of $11.60 billion, a P/E ratio of -44.65 and a beta of 3.72. The business’s 50-day moving average is $56.03 and its two-hundred day moving average is $52.27. Tempus AI has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. Analysts anticipate that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In related news, CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the completion of the sale, the chief executive officer owned 47,420 shares in the company, valued at $3,319,400. This represents a 23.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the transaction, the chief financial officer directly owned 106,024 shares in the company, valued at $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,043,988 shares of company stock worth $56,963,417 over the last 90 days. Company insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in TEM. ARK Investment Management LLC grew its holdings in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after buying an additional 381,816 shares during the last quarter. California State Teachers Retirement System lifted its position in Tempus AI by 6,379.2% during the 2nd quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock worth $404,189,000 after acquiring an additional 6,869,519 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. grew its stake in shares of Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Tempus AI by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock valued at $110,478,000 after purchasing an additional 141,680 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.